SGLT2 inhibitors block the reabsorption of glucose by inhibiting SGLT2, promoting glucose renal excretion, lowering the elevated glucose levels of patients with diabetes, and producing an osmotic diuretic effect [18–20]. This evidence concerns the gene SLC5A2 and diabetes mellitus.